CLSD earnings

ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter. Information about the Company's quarterly results, conference calls, webcasts and other investor information is available in the Investors section of the Company's website. About Clearside Biomedical, Inc. Clearsid

- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner's New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema Accepted for Regulatory Review in China - - Multiple Medical Meeting Presentations Highlight Potential Advantages and Key Differentiators of Suprachoroidal Drug Delivery Utilizing Clearside's SCS Microinjector® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 27, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the

ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2024 financial results will be reported on Thursday, March 27, 2025 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call ca

- Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a Differentiated Flexible Dosing Approach Similar to a Biologic with the Potential Extended Duration of a Tyrosine Kinase Inhibitor (TKI) - - Recent Commercial Licensing Agreement for China by a Global Ophthalmic Pharmaceutical Company Provides Strategic Validation of Clearside's Suprachoroidal Platform - - Compelling Data Presentations at AAO Demonstrated Potential Safety and Efficacy Benefits of Suprachoroidal Delivery Using Clearside's Proprietary SCS Microinjector® in Multiple Clinical Programs - - M

ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2024 financial results will be reported on Tuesday, November 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (877) 545-0523 (

- Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events - - 67% of CLS-AX Participants Did Not Require Any Additional Treatment up to 6 Months - - Reduced Treatment Burden by 84% Over 6 Months - - Webcast and Conference Call Today at 8:00 A.M. ET with Management and Key Opinion Leader and Board-Certified Retinal Specialist, Roger Goldberg, M.D., MBA - ALPHARETTA, Ga., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced

- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse Events Observed - - Recent Key Opinion Leader Webinar Highlighted the Broad Applicability and Real-World Experience of Suprachoroidal Drug Delivery - ALPHARETTA, Ga., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "Our P

ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2024 financial results will be reported on Monday, August 12, 2024, after the close of the financial markets. In lieu of a second quarter 2024 conference call, the Company hosted a Suprachoroidal Delivery Key Opinion Leader Webinar on Wednesday, July 24, 2024. The replay of this event is available on the Clearside website under the Investors section: Events and Presentations. Quarterly earnings conference calls are expected to

ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-645-4404 (U.S.) or

ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-50

- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside's Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5 Million Upfront, the Potential for Additional $77.5 Million in Clinical, Regulatory, and Sales Based Milestone Payments, Plus Royalties - - Recruitment Completed in CLS-AX Phase 2b ODYSSEY Wet AMD Trial with Topline Data Expected in Q3 2024 - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the e

ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2023 financial results will be reported on Monday, November 13, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (U.

- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO, ASRS and OIS Scientific Meetings - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. "The last several months have been very productive

ALPHARETTA, Ga., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2023 financial results will be reported on Monday, August 14, 2023 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (877) 545-0320 (U.

- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension Study Highlighted in Presentations at Recent Medical Meetings - - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga., May 11, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. "We have delivered a

ALPHARETTA, Ga., May 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. Registration for the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. To participate via telephone, please register in

- Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety Data, Durability, and Biologic Effect Over 6 Months - - Continued Growth in Retinal Specialists Trained in Suprachoroidal Space (SCS®) Injection Procedure Using FDA-Approved XIPERE® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 09, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today repo

ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2022 financial results will be reported on Thursday, March 9, 2023 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Registration for the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. To participate via telepho

- Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went at Least 6 Months Without Needing Additional Treatment - - Extension Participants Experienced a 77 - 85% Reduction in Treatment Burden Over 6 Months - - Webcast and Conference Call Today at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Mark R. Barakat, M.D. - ALPHARETTA, Ga., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal

- Favorable Safety Results, Durability and Biologic Effect Observed in Cohorts 3 and 4 of CLS-AX OASIS Phase 1/2a Trial - - Recent Positive Data Presentations Highlight the Potential Safety, Efficacy and Durability Benefits of Suprachoroidal Administration of Small Molecule Suspensions - - Management to Host Webcast and Conference Call on OASIS Data Today at 8:30 A.M. ET - ALPHARETTA, Ga., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter

- Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events - - Cohorts 3 and 4 Demonstrated Promising Signs of Durability, Biologic Effect, and a Meaningful Reduction in Treatment Burden - - Final 6-Month Data from Extension Study Expected in Q1 2023 - - Expect to Initiate Phase 2 Clinical Trial in Q1 2023 - - Webcast and Conference Call Today at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Arshad Khanani, M.D. - ALPHARETTA, Ga., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of

ALPHARETTA, Ga., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the Company will host a conference call on Wednesday, November 9, 2022 at 8:30 a.m. Eastern Time to report results from its OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD) patients. As previously announced, on November 9, 2022, Clearside will also report its financial results for the quarter ended September 30, 2022. The live and archived webcast may be acce

ALPHARETTA, Ga., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2022 financial results will be reported on Wednesday, November 9, 2022 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (888) 506-0062 (dom

- CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 - - Non-Dilutive Financing Agreement with HealthCare Royalty Supports Progression of CLS-AX Clinical Program - - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. "We are building significant momentum through our internal and partnered programs leveragi

ALPHARETTA, Ga., July 27, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2022 financial results will be reported on Tuesday, August 9, 2022 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. Registration for the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The Company suggests participants log in 15 mi

- First Approved Suprachoroidal Product, XIPERE®, Now Commercially Available in U.S. - - Cohort 4 Enrolling at 1.0 mg Dose in CLS-AX OASIS Wet AMD Phase 1/2a Trial - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., May 11, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. "The approval and recent commercial launch of XIPERE® in the U.S. validates delivery into the suprachoroidal sp

ALPHARETTA, Ga., April 29, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2022 financial results will be reported on Wednesday, May 11, 2022 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domest

- XIPERE® -Related Milestones Generated $20 Million in Non-Dilutive Funding in Q4 2021 - - Continued Progress in CLS-AX OASIS Wet AMD Phase 1/2a Trial with Cohort 3 Results Expected Mid-2022 - - New Cohort 4 Planned in Q2 2022 to Expand CLS-AX Dose Escalation in OASIS Trial- - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corpo

ALPHARETTA, Ga., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2021 financial results will be reported on Thursday, March 10, 2022 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 2

- Suprachoroidal Injection of CLS-AX 0.1 mg Dose Well-Tolerated in Cohort 2 with No Treatment Related Adverse Events –- Consistent Safety Profile Observed in Cohorts 1 and 2 Supports Advancement to Cohort 3 -- Webcast and Conference Call Today at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Peter Kaiser, M.D. - ALPHARETTA, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today positive safety results from OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) a

- XIPERE™ is First FDA-Approved Product for Injection into the Suprachoroidal Space - - Approval-Related Milestones to Provide $19 Million in Non-Dilutive Funding - - Continued Progress in CLS-AX Wet AMD Phase 1/2a Trial - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2021. "The approval of XIPERE™ marks a significant milestone for Clearside

ALPHARETTA, Ga., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2021 financial results will be reported on Wednesday, November 10, 2021 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (do

- Enrollment Underway in Cohort 2 of OASIS Wet AMD Phase 1/2a Trial with Data Expected by the End of 2021 – - Upcoming FDA PDUFA Action Date in October 2021 for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for second quarter ended June 30, 2021. "We continue to demonstrate our position as the leader in th

ALPHARETTA, Ga., July 27, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its second quarter 2021 financial results will be reported on Tuesday, August 10, 2021 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by di